A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
Completed · Phase 1 · NCT06475729
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $7.6M
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 498
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Citrate-Free Mirikizumab (drug)
- Dates
- Started 2024-06-24; completion 2024-12-27
- Results posted
- Yes
The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.
From ClinicalTrials.gov, last updated 2025-12-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $7.6M in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amina Z. Haggag, M.D. Family Medicine · Northridge, CA
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- Juan C. Rondon, MD Internal Medicine · Hollywood, FL
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
- Leea D. Reed, DO Family Medicine · Rogersville, MO
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $4.9M
- Anaheim Clinical Trials LLC $729,339
- Erg Holding Co LLC DBA St Louis Clinical Trials LLC $657,033
- Covance Clinical Research LP Dallas $435,389
- Fortrea Clinical Research Unit Inc $435,389
- Bio Kinetic Clinical Applications LLC $433,374
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.